Corindus Vascular Robotics announced that in addition to a talk focusing on robotics in the future of the cath lab, cases submitted by users of its CorPath Vascular Robotics system have been accepted for presentation at the Cardiovascular Research Technologies (CRT) conference on February 22 – 25, 2014 in Washington, DC, USA.
Terumo Corporation announced that it has received CE mark approval for its drug-eluting stent, “Ultimaster”. The company will launch the Ultimaster drug-eluting stent in Europe, Latin America, and Asia (excluding Japan) in June 2014.
New practice guidelines for the management of patients with valvular heart disease provide updated definitions of disease severity – categorising four progressive stages from “at risk” to “symptomatic severe” – and lower the threshold for intervention in select patient populations.
In a press release OrbusNeich announced that patient enrolment has been initiated in Japan in the clinical trial of the Combo dual therapy stent employing a single Japan-US protocol conducted as a Global Clinical Trial “proof-of-concept” under the framework of the joint Japan-US Harmonisation-By-Doing initiative. The first patient was enrolled at Shonan Kamakura General Hospital, Japan, by Shigeru Saito, the vice director of the hospital and co-principal investigator of the study.
Chiara Bernelli (Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy) and others report in JACC: Cardiovascular Interventions that, in patients undergoing transfemoral trancatheter aortic valve implantation (TAVI), baseline activated clotting time (ACT)-guided heparin administration is associated with significantly less bleeding than heparin administration that is guided by the patient’s weight alone.
A retrospective review, published ahead of print in Heart, has found that patients who did not fast before a percutaneous coronary intervention (PCI) procedure—either for elective PCI or for acute coronary syndrome—did not develop intraprocedural or postprocedural aspiration pneumonia. This indicates that the traditional practice of keeping patients nil-by-mouth prior to elective PCI may not always be necessary.---latest-news/fasting-may-not-be-necessa
In a UK first, experts from Glenfield Hospital have repaired a dysfunctional heart valve by inserting a tiny implant measuring just 23mm in size.
Doctors at The London Chest Hospital have administered the first patient’s own stem cells in the world’s largest-ever trial of adult stem cell therapy in heart attack patients.
The OrbusNeich Combo Dual Therapy stent was featured at the Joint Interventional Meeting (JIM) 2014 in Rome, February 13-15.
Cardiovascular Systems will release one-year data from the ORBIT II study of the company’s Diamondback 360 coronary orbital atherectomy system in treating severely calcified lesions. The data will be presented as an iMPACT Trial at the 2014 Cardiovascular Research Technologies conference in Washington, DC, USA (February 22-25, 2014).
Cardiac Dimensions announced that the company’s Carillon mitral contour system has received German Neue Untersuchungs und Behandlungsmethoden (NUB) Status 1 approval across 120 hospitals in Germany, a decision from German regulators that may positively influence reimbursement from insurance companies for the costs of Carillon procedures.
Claret Medical announced that it has received Investigational Device Exemption (IDE) approval from the Food and Drug Administration (FDA) for a multicentre study of the company’s Sentinel cerebral protection system for embolic protection during Transcatheter Aortic Valve Implantation (TAVI).
Surgeons in France have successfully replaced the aortic valve in two patients without opening the chest during surgery. The procedure, using totally endoscopic aortic valve replacement (TEAVR), shows potential for improving quality of life of heart patients by offering significantly reduced chest trauma. It is described in The Journal of Thoracic and Cardiovascular Surgery, an official publication of the American Association for Thoracic Surgery.
Recent developments surrounding the SynCardia temporary Total Artificial Heart will make the device available to three times the number of people suffering from end-stage biventricular heart failure. Over 300 SynCardia Hearts have been implanted worldwide since 2012.
Ganesh Athappan (Department of Cardiovascular Medicine, Heart & Vascular Medicine Institute, Case Western Reserve University, Cleveland, USA) and others report that their meta-analysis, published ahead of print in the Journal of the American College of Cardiology, of transcatheter aortic valve implantation (TAVI) studies indicates that the rate of post-TAVI stroke is similar between different valve designs (eg. CoreValve vs. Sapien) and approaches (eg. transapical vs. transfemoral).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos